The U.S. health regulator put on hold a trial designed to evaluate switching the prescription-only erectile dysfunction drug Cialis to an over-the-counter (OTC) treatment, French drugmaker Sanofi said on Monday.
Johnson & Johnson settled most of the lawsuits the company faced by thousands of men who claimed the anti-psychotic drug Risperdal caused them to develop excessive breast tissue and disclosed that J&J recorded $800 million in expenses in connection with the agreement.
AstraZeneca is selling European rights (excluding Spain and the UK) to the erstwhile blockbuster cholesterol drug Crestor to German pharmaceutical company Grünenthal as the British drugmaker focuses on cancer treatments.
Grünenthal agreed to acquire the European rights (excluding Spain and the UK) to AstraZeneca’s Crestor (rosuvastatin) and its associated brands for a total consideration of up to $350 million.
OxyContin maker Purdue Pharma pleads guilty to criminal chargesAddictions, Bankruptcy, Business, Criminal Charges, District Judges, Doctors, Former Blockbusters, Investigations, Kickbacks, New Jersey, OxyContin, Painkillers, Plea Deals, Purdue Pharma, Therapeutics, U.S. Justice Department, U.S. Opioid Crisis
Purdue Pharma LP pleaded guilty to criminal charges over the handling of the company’s addictive prescription painkiller OxyContin, capping a deal with federal prosecutors to resolve an investigation into the drugmaker’s role in the U.S. opioid crisis.
Mallinckrodt filed for bankruptcy protection, saddled with lawsuits alleging the company helped fuel the U.S. opioid epidemic.
The U.S. Food and Drug Administration removed a boxed warning about increased risk of leg and foot amputations with Johnson & Johnson’s diabetes drug Invokana.
Pfizer Inc. announced that the U.S. FDA approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen, for all eligible indications of the reference product.
The European Commission approved GlaxoSmithKline’s three-in-one inhaler Trelegy Ellipta for chronic lung disease.
AstraZeneca’s drug sales fell again in third-quarter 2017, hit by generic competition to former blockbusters such as the cholesterol pill Crestor, although the pace of decline slowed as the company looks to new cancer treatments to revive its fortunes.